First Nebraska Trust Co Takes $480,000 Position in Gilead Sciences, Inc. $GILD

First Nebraska Trust Co purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 3,802 shares of the biopharmaceutical company’s stock, valued at approximately $480,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Brighton Jones LLC lifted its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $215,000. Sivia Capital Partners LLC boosted its holdings in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares during the last quarter. Ieq Capital LLC raised its position in shares of Gilead Sciences by 12.0% in the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC lifted its stake in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider directly owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock valued at $11,562,960 over the last 90 days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $146.12 on Friday. The stock’s fifty day moving average is $131.97 and its two-hundred day moving average is $136.59. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.01 EPS. Equities analysts expect that Gilead Sciences, Inc. will post -0.51 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Royal Bank Of Canada upped their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 5th. Rothschild & Co Redburn dropped their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Barclays reduced their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.